Wednesday June 15, 2016
According to reports from PricewaterhouseCoopers, recent venture capital investments in the biopharmaceutical industry were some of the largest in history averaging $6B-$7B per year. Thanks to the ease of global monetary policy, the rapid increase in merger & acquisition (M&A) activities along with much easier access to public financing via IPO and robust revenue growth help fuel the venture ecosystem and provide a fertile ground for high-risk companies and young start-ups. The recent paradigm-shift innovations, such as immune-oncology and targeted therapies for previously incurable diseases, surely helped open up many doors of opportunities for both companies and investors alike.
The panelists will share their experiences and insights on both value creation via sound business model and innovation in disease treatments, which are the two important elements for growth and success. Effective partnership/M&A as well as ever-changing US/global regulatory challenges and opportunities will also be discussed.
Wednesday, June 15, 2016
|REGISTRATION / NETWORKING:||5:30 P.M. – 6:00 P.M.|
|PROGRAM:||6:00 P.M. – 8:15 P.M.|
|NETWORKING:||8:15 P.M. – 9:00 P.M.|
$15: Early Bird Discount for first 30 registrations by May 28 (11PM)
$20: Regular Registration by Sunday, June 11 (11 PM)
$35: Late Registration by Wednesday, June 13 (Noon)
$50: Walk-ins (Seats are limited and may not be available)
Food, including sushi and beverages, will be served.